An In Vitro Study to Evaluate the Synergy of Baptisia tinctoria against Salmonella typhi

Abstract

AbstractAs a consequence of gradual emergence of anti-microbial resistance, the anti-biogram profile of the microbe Salmonella typhi has undergone substantial changes. Patients frequently utilise homeopathy for the flu season and other serious illnesses. Although the use of Baptisia tinctoria (BT) is extensively described in homeopathic literature and in phytomedicine, scientific exploration has never been done. In this study, we have made an effort to understand the anti-typhoidal effect of BT at different concentrations. S. typhi (ATCC 6539) from a freshly prepared stock culture was used in this experiment. We also procured an international strain of Escherichia coli (ATCC 25922 strain) which was taken as control. The antibiotic susceptibility patterns of the isolates were determined by the Kirby-Bauer disc diffusion method according to the Clinical and Laboratory Standards Institute guidelines and interpretative criteria (National Committee for Clinical Laboratory Standards 2000) using antibiotic discs (Hi Media Laboratory. Pvt. Ltd., Mumbai, Maharashtra, India), namely cefotaxime (30 μg), ceftazidime (30 μg), ciprofloxacin (5 μg), tetracycline (30 μg), chloramphenicol (30 μg), streptomycin (10 μg), ampicillin (10 μg), gentamicin (10 μg), kanamycin (30 μg), nalidixic acid (30 μg) and trimethoprim (5 μg). BT in its 6CH potency showed the greatest growth inhibition zone, not just amidst the homeopathic potency gradient. It has shown the highest growth inhibition zone of 28mm, more than any conventional antibiotic. Ethanolic extract of BT can be considered to combat against array of infections caused by S. typhi species alongside that it can also be considered as adjuvant with conventional antibiotics for better result.